Security key
92243G108
Vaxcyte, Inc. - Common Stock, $0.001 par value per share (PCVX)
CUSIP: 92243G108
Q2 2024 13F Holders as of 30 Jun 2024
- Type / Class
- Equity / Common Stock, $0.001 par value per share
- Shares outstanding
- 145,782,011
- Total 13F shares
- 122,578,572
- Share change
- +3,493,818
- Total reported value
- $9,264,040,265
- Put/Call ratio
- 41%
- Price per share
- $75.51
- Number of holders
- 264
- Value change
- +$268,135,107
- Number of buys
- 151
- Number of sells
- 100
Report period
Q2 2024
Institutions
264
Top holders
10
PCVX full security history
Newer quarter: Q3 2024
Previous quarter: Q1 2024
Vaxcyte, Inc. SEC filings
Vaxcyte, Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 92243G108
Recent filing periods:
Top shareholders of PCVX - Vaxcyte, Inc. - Common Stock, $0.001 par value per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with the largest verified stakes, then open the linked filing trail.
13F
Large-stake signal
No latest 13D/G holder appears in this grouped view.
Evidence coverage
50 holder rows
Latest evidence as of 31 Mar 2024.
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| FMR LLC |
13F
Company
|
11%
|
$1,110,799,797
16,261,159 shares
|
— | 31 Mar 2024 |
| VANGUARD GROUP INC |
13F
Company
|
6.7%
|
$665,151,821
9,737,254 shares
|
— | 31 Mar 2024 |
| BlackRock Finance, Inc. |
13F
Company
|
6.5%
|
$649,833,509
9,513,007 shares
|
— | 31 Mar 2024 |
| RA CAPITAL MANAGEMENT, L.P. |
13F
Company
|
5.6%
|
$560,398,436
8,203,754 shares
|
— | 31 Mar 2024 |
| JANUS HENDERSON GROUP PLC |
13F
Company
|
5.3%
|
$524,117,484
7,673,868 shares
|
— | 31 Mar 2024 |
| WELLINGTON MANAGEMENT GROUP LLP |
13F
Company
|
3.4%
|
$336,042,164
4,919,370 shares
|
— | 31 Mar 2024 |
| Capital Research Global Investors |
13F
Company
|
2.8%
|
$282,838,990
4,140,521 shares
|
— | 31 Mar 2024 |
| T. Rowe Price Investment Management, Inc. |
13F
Company
|
2.4%
|
$242,704,000
3,552,967 shares
|
— | 31 Mar 2024 |
| STATE STREET CORP |
13F
Company
|
2.3%
|
$227,956,755
3,337,092 shares
|
— | 31 Mar 2024 |
| PRICE T ROWE ASSOCIATES INC /MD/ |
13F
Company
|
2.2%
|
$216,966,000
3,176,181 shares
|
— | 31 Mar 2024 |
| Darwin Global Management, Ltd. |
13F
Company
|
1.9%
|
$187,907,421
2,750,804 shares
|
— | 31 Mar 2024 |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
Company
|
1.6%
|
$156,272,989
2,287,375 shares
|
— | 31 Mar 2024 |
| FRANKLIN RESOURCES INC |
13F
Company
|
1.5%
|
$146,706,371
2,147,656 shares
|
— | 31 Mar 2024 |
| PERCEPTIVE ADVISORS LLC |
13F
Company
|
1.3%
|
$132,026,767
1,932,759 shares
|
— | 31 Mar 2024 |
| DRIEHAUS CAPITAL MANAGEMENT LLC |
13F
Company
|
1.3%
|
$127,589,896
1,867,807 shares
|
— | 31 Mar 2024 |
| ALLIANCEBERNSTEIN L.P. |
13F
Company
|
1.2%
|
$121,639,822
1,780,703 shares
|
— | 31 Mar 2024 |
| WESTFIELD CAPITAL MANAGEMENT CO LP |
13F
Company
|
1.1%
|
$108,346,149
1,586,095 shares
|
— | 31 Mar 2024 |
| FRED ALGER MANAGEMENT, LLC |
13F
Company
|
0.96%
|
$95,409,328
1,396,711 shares
|
— | 31 Mar 2024 |
| JENNISON ASSOCIATES LLC |
13F
Company
|
0.86%
|
$85,857,681
1,256,883 shares
|
— | 31 Mar 2024 |
| Paradigm Biocapital Advisors LP |
13F
Company
|
0.85%
|
$84,704,058
1,239,995 shares
|
— | 31 Mar 2024 |
| Invesco Ltd. |
13F
Company
|
0.85%
|
$84,329,310
1,234,509 shares
|
— | 31 Mar 2024 |
| BRAIDWELL LP |
13F
Company
|
0.83%
|
$82,839,742
1,212,703 shares
|
— | 31 Mar 2024 |
| JPMORGAN CHASE & CO |
13F
Company
|
0.8%
|
$79,360,987
1,161,777 shares
|
— | 31 Mar 2024 |
| Frazier Life Sciences Management, L.P. |
13F
Company
|
0.78%
|
$77,832,756
1,139,405 shares
|
— | 31 Mar 2024 |
| ORBIMED ADVISORS LLC |
13F
Company
|
0.73%
|
$72,827,409
1,066,131 shares
|
— | 31 Mar 2024 |
| NORGES BANK |
13F
Company
|
0.72%
|
$71,454,446
1,046,032 shares
|
— | 31 Mar 2024 |
| NORTHERN TRUST CORP |
13F
Company
|
0.66%
|
$66,175,790
968,757 shares
|
— | 31 Mar 2024 |
| Pictet Asset Management Holding SA |
13F
Company
|
0.59%
|
$58,853,978
861,569 shares
|
— | 31 Mar 2024 |
| Commodore Capital LP |
13F
Company
|
0.59%
|
$58,746,600
860,000 shares
|
— | 31 Mar 2024 |
| Novo Holdings A/S |
13F
Company
|
0.58%
|
$57,721,950
845,000 shares
|
— | 31 Mar 2024 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC |
13F
Company
|
0.57%
|
$56,944,446
833,618 shares
|
— | 31 Mar 2024 |
| Pivotal bioVenture Partners Investment Advisor LLC |
13F
Company
|
0.54%
|
$54,172,494
793,036 shares
|
— | 31 Mar 2024 |
| Kynam Capital Management, LP |
13F
Company
|
0.51%
|
$50,890,950
745,000 shares
|
— | 31 Mar 2024 |
| GOLDMAN SACHS GROUP INC |
13F
Company
|
0.48%
|
$47,713,988
698,492 shares
|
— | 31 Mar 2024 |
| Cormorant Asset Management, LP |
13F
Company
|
0.47%
|
$46,792,350
685,000 shares
|
— | 31 Mar 2024 |
| EVENTIDE ASSET MANAGEMENT, LLC |
13F
Company
|
0.45%
|
$44,893,742
657,206 shares
|
— | 31 Mar 2024 |
| Avoro Capital Advisors LLC |
13F
Company
|
0.39%
|
$39,278,250
575,000 shares
|
— | 31 Mar 2024 |
| MORGAN STANLEY |
13F
Company
|
0.34%
|
$33,502,922
490,454 shares
|
— | 31 Mar 2024 |
| Ensign Peak Advisors, Inc |
13F
Company
|
0.33%
|
$32,495,067
475,700 shares
|
— | 31 Mar 2024 |
| AMERICAN CENTURY COMPANIES INC |
13F
Company
|
0.32%
|
$31,540,382
461,724 shares
|
— | 31 Mar 2024 |
| FEDERATED HERMES, INC. |
13F
Company
|
0.29%
|
$29,082,983
425,750 shares
|
— | 31 Mar 2024 |
| Bank of New York Mellon Corp |
13F
Company
|
0.28%
|
$28,179,584
412,525 shares
|
— | 31 Mar 2024 |
| Woodline Partners LP |
13F
Company
|
0.27%
|
$26,893,920
393,704 shares
|
— | 31 Mar 2024 |
| LORD, ABBETT & CO. LLC |
13F
Company
|
0.26%
|
$26,256,000
384,363 shares
|
— | 31 Mar 2024 |
| FARALLON CAPITAL MANAGEMENT LLC |
13F
Company
|
0.26%
|
$25,780,194
377,400 shares
|
— | 31 Mar 2024 |
| D. E. Shaw & Co., Inc. |
13F
Company
|
0.25%
|
$25,086,779
367,249 shares
|
— | 31 Mar 2024 |
| MAVERICK CAPITAL LTD |
13F
Company
|
0.24%
|
$24,258,999
355,131 shares
|
— | 31 Mar 2024 |
| EAGLE ASSET MANAGEMENT INC |
13F
Company
|
0.23%
|
$22,608,124
338,800 shares
|
— | 31 Mar 2024 |
| Nuveen Asset Management, LLC |
13F
Company
|
0.21%
|
$21,268,455
311,352 shares
|
— | 31 Mar 2024 |
| SAMLYN CAPITAL, LLC |
13F
Company
|
0.21%
|
$20,676,003
302,679 shares
|
— | 31 Mar 2024 |
Institutional Holders of Vaxcyte, Inc. - Common Stock, $0.001 par value per share (PCVX) as of Q2 2024
As of 30 Jun 2024,
Vaxcyte, Inc. - Common Stock, $0.001 par value per share (PCVX) was held by
264 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
122,578,572 shares.
The largest 10 holders included
FMR LLC, BlackRock Inc., VANGUARD GROUP INC, JANUS HENDERSON GROUP PLC, RA CAPITAL MANAGEMENT, L.P., WELLINGTON MANAGEMENT GROUP LLP, Capital Research Global Investors, T. Rowe Price Investment Management, Inc., STATE STREET CORP, and PRICE T ROWE ASSOCIATES INC /MD/.
This page lists
265
institutional shareholders reporting positions in this security
for the Q2 2024 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q2 2024 vs Q1 2024 Across Filers
Q1 2024 holders
249
Q2 2024 holders
264
Holder diff
15
| Investor | Q1 2024 Shares | Q2 2024 Shares | Share Diff | Share Chg % | Q1 2024 Value $ | Q2 2024 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.